Download PDF

1. Company Snapshot

1.a. Company Description

MedinCell S.A. develops various therapeutic solutions.It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients.The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia.


Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain.The company is based in Jacou, France.

Show Full description

1.b. Last Insights on MEDCL

Medincell's recent performance was driven by advancements in its pharmaceutical pipeline, particularly with UZEDY, which continues to show strong growth. The company's partner, Teva, is preparing for a US NDA submission for Olanzapine LAI. Medincell also secured new grants, including one to combat malaria. Management presentations at various healthcare conferences have highlighted the company's value proposition. With a strong product pipeline and expanding portfolio, Medincell is well-positioned for future growth. The company will present its half-year financial results on December 9, 2025.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025

Dec -01

Source:

Card image cap

European Growth Companies With High Insider Ownership In December 2025

Dec -01

Source:

Card image cap

Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference

Nov -27

Source:

Card image cap

Medincell Awarded New Grant to Fight Malaria

Nov -24

Source:

Card image cap

Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025)

Nov -13

Source:

Card image cap

Evaluating MedinCell (ENXTPA:MEDCL): Is There Value Left After a 75% Year-to-Date Share Price Surge?

Nov -13

Source:

Card image cap

Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth

Nov -11

Source:

Card image cap

Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark

Nov -10

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.25%)

6. Segments

Products Received under Development Benefit

Expected Growth: 9.27%

MedinCell S.A.'s 9.27% growth in Products Received under Development Benefit is driven by increasing demand for innovative pharmaceutical products, strategic partnerships, and expansion into new markets. Additionally, advancements in drug delivery technologies and a strong pipeline of products in development contribute to this growth.

Licenses, Milestones

Expected Growth: 9.33%

MedinCell S.A.'s 9.33% growth is driven by increasing demand for its innovative, long-acting injectable therapies, successful partnerships and collaborations, and strategic licensing agreements. Milestones achieved in clinical trials, regulatory approvals, and product launches also contribute to its growth. The company's strong pipeline and expanding portfolio of licensed products further support its upward trajectory.

Royalties

Expected Growth: 8.9%

Strong demand for MedinCell's innovative drug delivery technologies, increasing partnerships with pharmaceutical companies, and successful product launches in new markets drive the 8.9% growth in royalties. Additionally, the expansion of MedinCell's intellectual property portfolio and rising sales of licensed products contribute to the growth.

7. Detailed Products

BEPO

A long-acting injectable formulation of risperidone for the treatment of schizophrenia

mdc-IRM

A long-acting injectable formulation of ivermectin for the prevention of river blindness

mdc-TTG

A long-acting injectable formulation of testosterone for the treatment of hypogonadism

mdc-COVID-19

A long-acting injectable formulation of ivermectin for the treatment of COVID-19

8. MedinCell S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

MedinCell S.A. operates in the pharmaceutical industry, where substitutes are available, but the company's innovative products and services reduce the threat of substitutes.

Bargaining Power Of Customers

MedinCell S.A. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products and services are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

MedinCell S.A. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size and reputation, suppliers still have some negotiating power.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs. This reduces the threat of new entrants for MedinCell S.A.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. MedinCell S.A. faces intense competition from other companies with similar products and services.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 428.65%
Debt Cost 7.62%
Equity Weight -328.65%
Equity Cost 9.15%
WACC 2.58%
Leverage -130.43%

11. Quality Control: MedinCell S.A. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Biotest

A-Score: 5.6/10

Value: 7.6

Growth: 7.4

Quality: 2.4

Yield: 0.0

Momentum: 6.0

Volatility: 10.0

1-Year Total Return ->

View Full Report
Stock-Card
Nanobiotix

A-Score: 5.3/10

Value: 10.0

Growth: 3.1

Quality: 8.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Bavarian Nordic

A-Score: 5.1/10

Value: 6.4

Growth: 9.0

Quality: 7.4

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
MedinCell

A-Score: 5.0/10

Value: 6.0

Growth: 7.0

Quality: 5.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Galapagos

A-Score: 3.9/10

Value: 8.0

Growth: 2.9

Quality: 5.0

Yield: 0.0

Momentum: 3.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Kuros Biosciences

A-Score: 3.7/10

Value: 4.0

Growth: 6.9

Quality: 4.1

Yield: 0.0

Momentum: 7.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

26.0$

Current Price

26$

Potential

-0.00%

Expected Cash-Flows